Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, highlighting significant growth for its flagship medication, Filspari. The company achieved quarterly net product sales of $126.6 million and a full-year total of $410.5 million, with Filspari alone generating $322 million in 2025, which was a 144% increase year-over-year. This growth was supported by expanded physicia ...

Core Insights - Palvella Therapeutics announced positive topline results from the Phase 3 SELVA study of QTORIN™ rapamycin for treating microcystic lymphatic malformations, meeting its primary endpoint with a statistically significant improvement [2][3] - The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026, with potential approval in the first half of 2027 [3][10] Study Results - The primary endpoint, the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA), showed a mean improvement of +2.13 points (p<0.001) [5][6] - 95% of participants aged ≥ 6 who completed the efficacy evaluation improved on the mLM-IGA at Week 24, with 86% rated as "Much Improved" or "Very Much Improved" [6][9] - All four secondary efficacy endpoints also achieved statistical significance (all p<0.001) [2][5] Safety and Tolerability - QTORIN™ rapamycin was well-tolerated, with no drug-related serious adverse events reported and systemic rapamycin levels below 2 ng/mL at all timepoints [6][8] - Among the 50 participants, 70% experienced treatment-emergent adverse events, but all were rated mild or moderate [8][9] Future Plans - Palvella aims to present detailed results from the SELVA study at upcoming medical meetings and is advancing QTORIN™ rapamycin for other rare skin diseases [11] - The company has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA for QTORIN™ rapamycin [10]

STAFFORD, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, including two corresponding posters. The ...

Leerink Partners sets a price target of $1 for Gossamer Bio Inc. (NASDAQ:GOSS), suggesting a potential increase of about 63.76%.The company's Phase 3 PROSERA study on seralutinib for PAH showed potential efficacy but missed a key statistical threshold.Gossamer Bio's stock has experienced a significant decrease, currently priced at $0.42, reflecting an 80.13% decrease in value.Gossamer Bio Inc. (NASDAQ:GOSS) is a biopharmaceutical company focused on developing treatments for pulmonary arterial hypertension ( ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best value stocks to buy now. On February 17, Bristol Myers Squibb announced that the FDA accepted its NDA for iberdomide, which is an investigational treatment for patients with relapsed or refractory multiple myeloma/RRMM. If approved, iberdomide would become the first in a new class of oral medicines known as cereblon E3 ligase modulator agents. The FDA granted the application Priority Review and Breakthrough Therapy Designation, setting a target act ...

AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20, the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults with chronic lymphocytic leukemia/CLL. This establishes the first and only all-oral, fixed-duration regimen for previously untreated patients, providing a new alternative to traditional chemoimmunotherapy. By combining two classes of oral medications, the treatment offers patients the potential for periods ...

Core Viewpoint - Avacta Therapeutics has demonstrated that its proprietary pre|CISION platform offers significant advantages over the marketed antibody drug conjugate (ADC) Enhertu, with plans to initiate a clinical trial for FAP-Exd (AVA6103) in Q1 2026 [1][3]. Group 1: Clinical Data and Comparisons - The analysis compares the delivery profile of pre|CISION FAP-cleavable payload with Enhertu, which is approved for breast and gastric cancer [3]. - The pre|CISION platform shows three key advantages: faster drug penetration into tumors, a higher maximum drug concentration in tumors, and a nearly three-fold higher Tumor Selectivity Index compared to Enhertu [4][9]. - The maximum concentration (Cmax) of FAP-Exd in tumor tissue occurs within minutes, while T-Dxd reaches its maximum concentration at 24 hours [9]. Group 2: Mechanism and Efficacy - The pre|CISION delivery mechanism is designed to selectively deliver potent payloads to tumors while minimizing exposure to normal tissues, enhancing safety and effectiveness [11][13]. - The analysis indicates that FAP-Exd shows higher activity in tumor models with low FAP expression compared to T-Dxd's variable activity at low HER2 expression levels [7]. - Deep and durable responses were observed with FAP-Exd, persisting for weeks after a three-dose regimen [7]. Group 3: Future Plans and Innovations - Avacta plans to present these findings at an upcoming scientific congress and submit them to a peer-reviewed journal [8]. - The use of AI to create a synthetic comparator arm for data analysis highlights the innovative approach of the company's research team [5][6].

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) demonstrates a strong Return on Invested Capital (ROIC) of 20.84% compared to its Weighted Average Cost of Capital (WACC) of 9.83%, indicating efficient capital utilization.ACADIA Pharmaceuticals leads with the highest ROIC to WACC ratio among peers, suggesting superior efficiency and growth potential.Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biopharmaceutical company that focuses on developing medicines that treat intractable diseases by silencing the ...

BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on developing treatments for genetic conditions. The company is set to release its quarterly earnings on February 24, 2026. Wall Street anticipates an earnings per share (EPS) of -$0.75 and revenue of around $149.1 million. BBIO will also host a conference call to discuss these results and provide business updates.BBIO's financial metrics reveal some challenges. The company has a negative price-to-earnings (P/E) ratio of -16.23, in ...

Core Insights - Supernus Pharmaceuticals, Inc. is actively participating in multiple investor conferences in March 2026, showcasing its commitment to engaging with investors and stakeholders in the biopharmaceutical sector [1][2][3]. Conference Participation - The company will attend the TD Cowen 46th Annual Health Care Conference on March 2, 2026, with a fireside chat scheduled for 2:30 p.m. ET in Boston, Massachusetts [1]. - Supernus will also participate in the Jefferies Biotech on the Beach Summit on March 10, 2026, held in Miami Beach, Florida [2]. - Additionally, the company is set to present at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, with a fireside chat at 2:00 p.m. ET in Miami Beach, Florida [3]. Webcast Availability - Live audio webcasts of the TD Cowen and Barclays Conference presentations will be accessible on the Supernus Pharmaceuticals website, with archived replays available for 60 days post-conference [4]. Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases, indicating a specialized niche within the biopharmaceutical industry [5]. - The company's neuroscience portfolio includes approved treatments for various conditions such as ADHD, Parkinson's disease-related dyskinesia, postpartum depression, epilepsy, and migraine, among others [6].